ticagrelor

Ligand id: 1765

Name: ticagrelor

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: ticagrelor

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 10
Hydrogen bond donors 4
Rotatable bonds 10
Topological polar surface area 163.74
Molecular weight 522.19
XLogP 2.09
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Approved as an anti-coagulant, for use in patients with acute coronary syndromes or peripheral vascular diseases. Normally used together with aspirin (acetylsalicylic acid). May also be used long-term in patients with a history of heart attack.
Mechanism Of Action and Pharmacodynamic Effects
Ticagrelor is a negative allosteric modulator of the P2Y12 receptor. Ticagrelor treatment leads to impaired ADP-mediated activation of the integrin αIIbβ3 complex on platelet membranes which normally binds fibrinogen. This action inhibits fibrinogen-induced aggregation of platelets, thereby reducing clot formation.
External links